Janat Chemusto Handed 4-Year Ban for Doping Violation

Uganda’s middle-distance runner Janat Chemusto has been handed a four-year ban by the Athletics Integrity Unit (AIU).

The ban follows the discovery of a Prohibited Substance (19-norandrosterone), linked to the use of Nandrolone or its precursors, in her system.

Chemusto’s exceptional performance in the 1500m event at the Kip Keino Classic in Nairobi, where she clocked a remarkable personal best time of 4:01.81, now faces disqualification.

The AIU ruling mandates the disqualification of her results from 13 May 2023 onwards, stripping her of any titles, awards, medals, points, prizes, and appearance money earned during that period.

Chemusto is a 2014 Commonwealth Youth Games 3000m bronze medallist.

She became the second fastest Ugandan athlete in 1500m with a time of 4:01.79 lagging behind the National record holder, Winnie Nanyondo who holds the time of 3:59.56.

She was provisionally suspended by Athletics Integrity Unit (AIU) for the presence/use of a Prohibited substance in September this year, and consequently missed the World Athletics Championships in Budapest.

The World Anti-Doping Agency (WADA) accredited laboratory in Lausanne, Switzerland, reported an Adverse Analytical Finding in Chemusto’s urine sample, citing the presence of 19-Norandrosterone, a metabolite linked to Nandrolone, classified as a prohibited substance under the WADA 2023 Prohibited List.

The Athletics Integrity Unit (AIU) reviewed the case, finding that Chemusto lacked a Therapeutic Use Exemption (TUE) for the detected substance and detected no procedural deviations leading to the Adverse Analytical Finding.

Chemusto, through her legal representative, provided an initial explanation attributing the presence of the banned substance to medications prescribed in January and April 2023. However, subsequent medical documents failed to substantiate this claim.

Consequently, on 14 September 2023, the AIU issued a Notice of Charge against Chemusto, asserting Anti-Doping Rule Violations under Rule 2.1 ADR and Rule 2.2 ADR.



Leave a Reply

Your email address will not be published. Required fields are marked *